• N/A
    Market Cap
  • -91.67%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 68
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.

Fifty 1 Labs Inc. has signed a Letter of Intent to acquire BioSpark AI Technologies Inc., a Vancouver-based AI company specializing in clinical data extraction and analysis. The proposed acquisition involves 25 million common shares and aims to strengthen Fifty 1 Labs' position in AI-powered healthcare solutions.

09/30/2025, 9:56 AM • Benzinga

Peers

Statistics

More
Day Range
$0.0001
$0.0001
$0.0001
1-Year Range
$0.0001
$0.002
$0.0001
Latest Close$0.0001
Change
$0.00 (0.00%)
Volume16,345,160

Information as of 11/12/2026

Company Profile

Fifty 1 Labs, Inc.
https://fifty1labs.com
N/A
Market Cap
N/A
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
1505 W 2nd Ave, Vancouver, BC, Canada, V6J 1H2
877 505 5006

Fifty 1 Labs, Inc., a biotechnology and life sciences company, which focuses on peptide products, peptide discovery, AI-enabled research, and clinical development in the United States. The company provides sports supplements; peptides; telepath products, as well as health and wellness solutions. It offers supplements such as, pre-workout formulas, BCAAS, ION+ electrolyte formula, turmeric gummies, and ashwagandha gummies. The company was formerly known as Consumer Automotive Finance, Inc. and changed its name to Fifty 1 Labs, Inc. in March 2025. Fifty 1 Labs, Inc. was incorporated in 1998 and is based in Vancouver, Canada.

Key Executives

  • Alind Gupta
  • Joel Gagnier
  • Nima Sakian
  • Brandon Spikes
  • Martin Mills

Current Ownership Distribution

  • Other571.9M (100.00%)
  • Insiders9,500 (0.002%)
  • Institutions0 (0.00%)
  • Mutual Funds0 (0.00%)